pamidronate has been researched along with Osteosarcoma in 18 studies
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma." | 9.15 | Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. ( Abramson, SJ; Chou, AJ; Gorlick, R; Healey, JH; Kellick, MG; Laquaglia, MP; Merola, PR; Meyers, PA; Morris, CD; Wexler, LH, 2011) |
| "After observing metaphyseal changes in pediatric and young adult patients with osteosarcoma who were treated with pamidronate, we initiated a retrospective study to identify bone findings on computed radiography of the chest and extremities, chest CT, extremity MRI, and radionuclide bone scans in this population." | 7.77 | Skeletal imaging effects of pamidronate therapy in osteosarcoma patients. ( Abramson, SJ; Bartolotta, R; Chou, A; Hwang, S; Katz, DS; Meyers, P; Price, AP, 2011) |
| "To evaluate in vitro biological activity of gemcitabine, alone and in combination with Pamidronate or carboplatin, against canine osteosarcoma (OSA) cell lines." | 7.76 | Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. ( Bear, MD; Kulp, SK; London, CA; McMahon, MB; Pennell, ML, 2010) |
| "To determine the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells and non-neoplastic cells from dogs." | 7.73 | Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. ( Ashton, JA; Farese, JP; Lee-Ambrose, LM; Milner, RJ; van Gilder, JM, 2005) |
| "Canine osteosarcoma is a devastating disease with an overall poor prognosis." | 5.51 | Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells. ( Boston, S; Hoddinott, K; Mutsaers, AJ; Oblak, ML; Wood, GA, 2019) |
| "This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma." | 5.15 | Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. ( Abramson, SJ; Chou, AJ; Gorlick, R; Healey, JH; Kellick, MG; Laquaglia, MP; Merola, PR; Meyers, PA; Morris, CD; Wexler, LH, 2011) |
| " This is a follow-up study, its purpose was to examine the effects in-vitro of intravenous zoledronic acid (ZOL) and pamidronate (PAM) and oral alendronate (FOS) on the human oral cavity using gingival fibroblasts and osteoblasts cells and, in addition, osteogenic sarcoma cells (SaOS-2-cells)." | 3.78 | The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. ( Açil, Y; Gassling, V; Möller, B; Niehoff, P; Rachko, K; Simon, MJ; Wiltfang, J, 2012) |
| "After observing metaphyseal changes in pediatric and young adult patients with osteosarcoma who were treated with pamidronate, we initiated a retrospective study to identify bone findings on computed radiography of the chest and extremities, chest CT, extremity MRI, and radionuclide bone scans in this population." | 3.77 | Skeletal imaging effects of pamidronate therapy in osteosarcoma patients. ( Abramson, SJ; Bartolotta, R; Chou, A; Hwang, S; Katz, DS; Meyers, P; Price, AP, 2011) |
| "The gross volume and mineralization of osteosarcoma lesions were evaluated in living mice simultaneously with dual-channels by NIR dye-labeled probes, 2-deoxyglucose (DG) and pamidronate (OS), respectively." | 3.77 | In-vivo near-infrared optical imaging of growing osteosarcoma cell lesions xenografted in mice: dual-channel quantitative evaluation of volume and mineralization. ( Kawase, T; Nakayama, H; Okuda, K; Wolff, LF; Yoshie, H, 2011) |
| "To evaluate in vitro biological activity of gemcitabine, alone and in combination with Pamidronate or carboplatin, against canine osteosarcoma (OSA) cell lines." | 3.76 | Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. ( Bear, MD; Kulp, SK; London, CA; McMahon, MB; Pennell, ML, 2010) |
| " In this study, we investigated the possible direct effect of three N-containing BPs (alendronate, pamidronate, and zoledronate) on the specific activity of bone ALP obtained from an extract of UMR106 rat osteosarcoma cells." | 3.73 | Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. ( Cortizo, AM; McCarthy, AD; Vaisman, DN, 2005) |
| "To determine the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells and non-neoplastic cells from dogs." | 3.73 | Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. ( Ashton, JA; Farese, JP; Lee-Ambrose, LM; Milner, RJ; van Gilder, JM, 2005) |
| "Canine osteosarcoma is a devastating disease with an overall poor prognosis." | 1.51 | Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells. ( Boston, S; Hoddinott, K; Mutsaers, AJ; Oblak, ML; Wood, GA, 2019) |
| " The LD50 of i." | 1.27 | Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma. ( Blum, H; Möller, H; Pittermann, W; Pool, BL; Schmähl, D; Sinn, HJ; Spring, H; Sterz, H; Wingen, F, 1986) |
| " No significant increase in the median survival time of tumor-bearing animals was achieved at the two dosage schemes tested, i." | 1.27 | Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma. ( Schmähl, D; Wingen, F, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Hoddinott, K | 2 |
| Oblak, ML | 3 |
| Wood, GA | 2 |
| Boston, S | 2 |
| Mutsaers, AJ | 2 |
| Kozicki, AR | 1 |
| Robat, C | 1 |
| Chun, R | 1 |
| Kurzman, ID | 1 |
| Pagano, C | 1 |
| Boudreaux, B | 1 |
| Shiomitsu, K | 1 |
| McMahon, MB | 1 |
| Bear, MD | 1 |
| Kulp, SK | 1 |
| Pennell, ML | 1 |
| London, CA | 1 |
| Price, AP | 1 |
| Abramson, SJ | 2 |
| Hwang, S | 1 |
| Chou, A | 1 |
| Bartolotta, R | 1 |
| Meyers, P | 1 |
| Katz, DS | 1 |
| Meyers, PA | 1 |
| Healey, JH | 1 |
| Chou, AJ | 1 |
| Wexler, LH | 1 |
| Merola, PR | 1 |
| Morris, CD | 1 |
| Laquaglia, MP | 1 |
| Kellick, MG | 1 |
| Gorlick, R | 1 |
| Nakayama, H | 1 |
| Kawase, T | 1 |
| Okuda, K | 1 |
| Wolff, LF | 1 |
| Yoshie, H | 1 |
| Açil, Y | 1 |
| Möller, B | 1 |
| Niehoff, P | 1 |
| Rachko, K | 1 |
| Gassling, V | 1 |
| Wiltfang, J | 1 |
| Simon, MJ | 1 |
| Boston, SE | 1 |
| Higginson, G | 1 |
| Patten, SG | 1 |
| Monteith, GJ | 1 |
| Woods, JP | 1 |
| Vaisman, DN | 1 |
| McCarthy, AD | 1 |
| Cortizo, AM | 1 |
| Ashton, JA | 1 |
| Farese, JP | 1 |
| Milner, RJ | 1 |
| Lee-Ambrose, LM | 1 |
| van Gilder, JM | 1 |
| Garnero, P | 1 |
| Grimaux, M | 1 |
| Seguin, P | 1 |
| Delmas, PD | 1 |
| Mackie, PS | 1 |
| Fisher, JL | 1 |
| Zhou, H | 1 |
| Choong, PF | 1 |
| Sonnemann, J | 1 |
| Eckervogt, V | 1 |
| Truckenbrod, B | 1 |
| Boos, J | 1 |
| Winkelmann, W | 1 |
| van Valen, F | 1 |
| Klenner, T | 1 |
| Wingen, F | 3 |
| Keppler, BK | 1 |
| Krempien, B | 1 |
| Schmähl, D | 3 |
| Sterz, H | 1 |
| Blum, H | 1 |
| Möller, H | 1 |
| Pittermann, W | 1 |
| Pool, BL | 1 |
| Sinn, HJ | 1 |
| Spring, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pamidronate and Osteosarcoma
| Article | Year |
|---|---|
Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2015 |
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diphos | 2011 |
16 other studies available for pamidronate and Osteosarcoma
| Article | Year |
|---|---|
Effect of timing of bisphosphonate administration on canine osteosarcoma cells undergoing radiation therapy.
Topics: Animals; Bone Density Conservation Agents; Cell Line, Tumor; Cell Survival; Dog Diseases; Dogs; Drug | 2020 |
Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells.
Topics: Animals; Bone Density Conservation Agents; Cell Line, Tumor; Cell Survival; Dogs; Dose-Response Rela | 2019 |
SAFETY AND TOXICITY OF AN ACCELERATED COARSELY FRACTIONATED RADIATION PROTOCOL FOR TREATMENT OF APPENDICULAR OSTEOSARCOMA IN 14 DOGS: 10 GY × 2 FRACTIONS.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates | 2016 |
Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis | 2010 |
Skeletal imaging effects of pamidronate therapy in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Cisplatin; Diphosphonates; Doxorubi | 2011 |
In-vivo near-infrared optical imaging of growing osteosarcoma cell lesions xenografted in mice: dual-channel quantitative evaluation of volume and mineralization.
Topics: Animals; Bone Neoplasms; Calcification, Physiologic; Diphosphonates; Feasibility Studies; Inositol; | 2011 |
The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells.
Topics: Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Cell Line, Tumor; Cell Prolifer | 2012 |
The impact of pamidronate and chemotherapy on survival times in dogs with appendicular primary bone tumors treated with palliative radiation therapy.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Dog Disea | 2012 |
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diph | 2005 |
Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Diphosphonates; Dog Diseases | 2005 |
Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.
Topics: Adult; Antibodies, Monoclonal; Bone Diseases, Metabolic; Bone Neoplasms; Cell Line; Diphosphonates; | 1994 |
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carrier Proteins; Cell Division; Clodroni | 2001 |
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Division; Clodronic Acid; Diphosphonates; DNA Fragmentat | 2001 |
Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?
Topics: Animals; Bone and Bones; Bone Neoplasms; Carcinoma 256, Walker; Diphosphonates; Drug Evaluation, Pre | 1990 |
Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma.
Topics: Animals; Antineoplastic Agents; Body Temperature; Body Weight; Bone and Bones; Bone Development; Bro | 1986 |
Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma.
Topics: Animals; Autoradiography; Bone Neoplasms; Diphosphonates; Electrolytes; Male; Neoplasm Metastasis; N | 1985 |